<DOC>
	<DOCNO>NCT00005648</DOCNO>
	<brief_summary>The purpose study compare effectiveness gemcitabine without tipifarnib ( R115777 ) patient advanced pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine With Without Tipifarnib ( R115777 ) Treating Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither investigator patient know identity assign treatment ) compare overall survival patient advance pancreatic cancer treatment gemcitabine without tipifarnib ( referred R115777 ) . Gemcitabine approve chemotherapy agent administer intravenously ( iv ) ( though vein ) patient advanced pancreatic cancer . R115777 orally ( mouth ) administer investigational drug test combination gemcitabine treatment patient advance pancreatic cancer . Patients continue receive treatment gemcitabine R115777 ( placebo ) unless disease progression unacceptable toxicity observe . All patient study follow study assessment safety 5 year , start treatment , death ( whichever come first ) . R115777 ( match placebo ) 200 mg orally administer interval approximately 12 hour daily throughout study . Gemcitabine administer iv start dose 1000 mg/m2 every week first 7 week , follow 1 week rest , every 3 4 week thereafter . Treatment gemcitabine tipifarnib ( placebo ) continue 5 year ( start treatment ) absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>Pathological ( confirm biopsy ) diagnosis pancreatic cancer Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 ( define patient symptom pancreatic cancer fully active symptom able light work ) Have absolute neutrophil ( white blood cell ) count , platelet count ( blood clot factor ) , result liver function test consider investigator significantly abnormal Newly diagnose disease potential curative surgical resection Prior therapy chemotherapy , systemic therapy pancreatic cancer Have cardiovascular disease consider investigator uncontrolled severe</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Stage II pancreatic cancer</keyword>
	<keyword>Stage III pancreatic cancer</keyword>
	<keyword>Recurrent pancreatic cancer</keyword>
	<keyword>Adenocarcinoma pancreas</keyword>
	<keyword>Stage IV pancreatic cancer</keyword>
</DOC>